Inventiva (NASDAQ:IVA) Receives “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Inventiva (NASDAQ:IVA) in a research note released on Tuesday,Benzinga reports. They currently have a $20.00 price target on the stock.

Several other research analysts have also weighed in on IVA. Guggenheim increased their price objective on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Piper Sandler initiated coverage on Inventiva in a report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price objective on the stock. Finally, HC Wainwright assumed coverage on Inventiva in a report on Wednesday, September 3rd. They set a “buy” rating and a $20.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Inventiva currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

Inventiva Price Performance

Shares of IVA stock opened at $5.79 on Tuesday. The business has a 50-day simple moving average of $4.72 and a 200-day simple moving average of $3.78. Inventiva has a 52-week low of $1.60 and a 52-week high of $6.50.

Hedge Funds Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC raised its position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,558 shares of the company’s stock after purchasing an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 as of its most recent filing with the Securities and Exchange Commission. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.